NCT06047717 Vision Loss Impact on Navigation in Virtual Reality
| NCT ID | NCT06047717 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rochester |
| Condition | Stroke, Ischemic |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-11-28 |
| Primary Completion | 2028-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-11-28 with a primary completion date of 2028-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to better understand the impact of cortically-induced blindness (CB) and the compensatory strategies subjects with this condition may develop on naturalistic behaviors, specifically, driving. Using a novel Virtual Reality (VR) program, the researchers will gather data on steering behavior in a variety of simulated naturalistic environments. Through the combined use of computer vision, deep learning, and gaze-contingent manipulations of the visual field, this work will test the central hypothesis that changes to visually guided steering behaviors in CB are a consequence of changes to the visual sampling and processing of task-related motion information (i.e., optic flow).
Eligibility Criteria
Cortically Blind Group: Inclusion Criteria: * Residents of the United States or Canada * Presence of one-sided stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range of 21 - 75 years (verified by MRI and/or CT scans) * Reliable visual field defects in both eyes (homonymous defects) as measured by Humphrey or equivalent perimetry. * Willing, able, and competent to provide their own informed consent * Cognitively able, responsible to understand written and oral instructions in English * Emmetropic or else wear corrective contact lenses inside the virtual reality headset Exclusion Criteria: * Those who have never driven or earned a drivers' license * Past or present ocular disease interfering with visual acuity * Best corrected visual acuity (BCVA) worse than 20/40 in either eye * Sustained damage to the dorsal lateral geniculate nucleus * Presence of diffuse, whole-brain degenerative processes * Presence of brain damage deemed by study staff to potentially interfere with outcome measures * History of traumatic brain injury * Documented history of drug/alcohol abuse * Diagnosis of cognitive or seizure disorders * Diagnosis of one-sided attentional neglect Control Group: Inclusion Criteria: * Normal or corrected-to-normal vision, who are between the ages of 21 and 75 years of age, roughly matched to the age of CB subjects enrolled above * Competent and responsible, as determined by the Principal Investigator * Willing, able, and competent to provide their own informed consent * Normal cognitive abilities, be able to understand written and oral instructions in English * Emmetropic or else wear corrective contact lenses inside the virtual reality headset Exclusion Criteria: * Subjects who have never driven or earned a drivers' license * BCVA worse than 20/40 in either eye * Presence of vision loss from ocular diseases or disorders * Presence of a visual field defect * Inability to wear corrective contact lenses inside the virtual reality helmet if required to see clearly * Subjects with a history of neurological disorders * Subjects with a history of TBI * Persons who lack the competence or are otherwise unable to perform the visual testing as directed.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06047717 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 75 Years, studying Stroke, Ischemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06047717 currently recruiting?
Yes, NCT06047717 is actively recruiting participants. Contact the research team at Evan_Burr@URMC.Rochester.edu for enrollment information.
Where is the NCT06047717 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06047717 clinical trial?
NCT06047717 is sponsored by University of Rochester. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.